Premium
P3‐242: An Innovative outreach and service model of African‐American recruitment for Alzheimer's research
Author(s) -
Farrar Dorothy,
GreenHarris Gina,
Norris Nia,
Houston Stephanie,
Soryal Soryal,
Sager Mark
Publication year - 2011
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2011.05.1683
Subject(s) - outreach , grassroots , health equity , ethnic group , medicine , gerontology , public health , service (business) , family medicine , nursing , political science , business , marketing , politics , law
2010 who reported using FOS before study entry to those not using FOS prior to entering the study. The co-primary outcomes are the rates of change over time in 1) cognition using the cognitive subscale of the Alzheimer’s Disease Assessment Scale (ADAS-cog), and 2) whole brain and hippocampal atrophy determined by serial magnetic resonance imaging (MRI). Longitudinal outcomes for three groups cognitive normals, mild cognitive impairment (MCI), and those diagnosed with AD, stratified by ApoE 4 status, will be analyzed using mixed effect regression models to account for within subject clustering. Mean outcomes will be regressed on time (baseline through 48 month follow-up) and reported use of FOS (days), while controlling for potential confounders (including age, gender, education, race, cardiovascular risk, history of diabetes, smoking history, baseline cognition). In addition, models will include random intercepts. Models will be fitted separately for normals versus MCI and AD groups (which will be adjusted for use of cholinesterase inhibitors/ memantine). Results: Data analysis in process; results available March 2011. Conclusions: A growing body of evidence suggests that the pleiotropic effects of n-3 PUFAs play an essential role in brain health and cardiovascular homeostasis. The neuropathological processes that lead to AD and other dementias occur years before clinical symptoms appear and support the hypothesis that effectiveness of some therapeutic interventions may be timing dependant. A finding that early use of FOS by cognitively normal or at-risk individuals is associated with slowing or stabilization of markers of cognitive decline over time would motivate future AD prevention trials of this low cost, low-risk supplement in middle-aged and older adult populations.